비임상 약리학 및 독성학 규제 컨설팅 아웃소싱 시장 규모, 점유율 및 동향 분석 보고서 : 서비스별, 용도별, 방법별, 치료 영역별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Nonclinical Pharmacology And Toxicology Regulatory Consulting Outsourcing Market Summary

The global nonclinical pharmacology and toxicology regulatory consulting outsourcing market size was estimated at USD 0.965 billion in 2025 and is projected to reach USD 2.39 billion by 2033, growing at a CAGR of 12.2% from 2026 to 2033. The market growth is driven by the growing global drug development landscape, increasing drug discovery and development activities by pharmaceutical & biotechnology companies.

In addition, increased demand for expert regulatory guidance during the preclinical stages and stringent regulatory requirements from authorities such as the U.S. FDA and the European Medicines Agency, which require comprehensive safety and pharmacology data before the clinical trials, are other key driving factors contributing to the market growth.

The market for nonclinical pharmacology and toxicology regulatory consulting outsourcing is driven by the growing complexity of biologics and advanced therapies, increasing global regulatory scrutiny and safety mandates, an increase in decentralized trials, and a paradigm shift toward new approach methodologies (NAMs).

In addition, increasing shift from conventional small-molecule drugs to complex biologics and advanced therapeutic modalities is a major factor driving the growth of the global nonclinical pharmacology and toxicology regulatory consulting outsourcing market. The biopharmaceutical pipeline is rapidly expanding, with modalities such as cell and gene therapies, multi-specific antibodies, RNA-based therapeutics, and gene-editing platforms that require highly specialized preclinical evaluation strategies.

Global Nonclinical Pharmacology And Toxicology Regulatory Consulting Outsourcing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global nonclinical pharmacology and toxicology regulatory consulting outsourcing market report based on service, application, modality, therapeutic area, end use, and region:

• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Regulatory Strategy & Nonclinical Development Planning
• IND / CTA-Enabling Nonclinical Program Design
• Regulatory Gap Analysis & Risk Assessment
• Data Interpretation & Regulatory Writing
• Lifecycle & Post-IND Nonclinical Consulting
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Pre-IND Stage
• IND / CTA Submission Support
• BLA / MAA
• Others
• Modality Outlook (Revenue, USD Million, 2021 - 2033)
• Small Molecules
• Biologics (mAbs, Proteins)
• Cell and Gene Therapies
• Others
• Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Autoimmune & Inflammatory Diseases
• CNS
• Cardiovascular & Metabolic
• Infectious Diseases
• Rare Diseases
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical and Biopharmaceutical Companies
• Academic and Research Institutes
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Thailand
  • South Korea
  • Australia
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Service
  • 1.2.2. Application
  • 1.2.3. Modality
  • 1.2.4. Therapeutic Area
  • 1.2.5. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Botton-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing Complex Biologics and Advanced Therapies
    • 3.2.1.2. Increasing Global Regulatory Scrutiny and Safety Mandates
    • 3.2.1.3. Increase In Decentralized Trials
    • 3.2.1.4. Paradigm Shift Toward New Approach Methodologies (NAMS)
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Rising Cost Pressures And R&D Budget Constraints
    • 3.2.2.2. Shortage Of Specialized Scientific and Regulatory Talent
• 3.3. Technological Advancements
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Value Chain Analysis
  • 3.6.1. Supply Trends
  • 3.6.2. Demand Trends
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Force Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market: Service Estimates & Trend Analysis

• 4.1. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market, By Service: Segment Dashboard
• 4.2. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market, By Service: Movement Analysis
• 4.3. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
• 4.4. Regulatory Strategy & Nonclinical Development Planning
  • 4.4.1. Regulatory Strategy & Nonclinical Development Planning Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. IND / CTA-Enabling Nonclinical Program Design
  • 4.5.1. IND / CTA-Enabling Nonclinical Program Design Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Regulatory Gap Analysis & Risk Assessment
  • 4.6.1. Regulatory Gap Analysis & Risk Assessment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Data Interpretation & Regulatory Writing
  • 4.7.1. Data Interpretation & Regulatory Writing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Lifecycle & Post-IND Nonclinical Consulting
  • 4.8.1. Lifecycle & Post-IND Nonclinical Consulting Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.9. Others
  • 4.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market: Application Estimates & Trend Analysis

• 5.1. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market, By Application: Segment Dashboard
• 5.2. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market, By Application: Movement Analysis
• 5.3. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market Estimates & Forecasts, By Application, 2021 - 2033 (USD Million)
• 5.4. Pre-IND Stage
  • 5.4.1. Pre-IND Stage Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. IND / CTA Submission Support
  • 5.5.1. IND / CTA Submission Support Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. BLA / MAA
  • 5.6.1. BLA / MAA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market: Modality Estimates & Trend Analysis

• 6.1. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market, By Modality: Segment Dashboard
• 6.2. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market, By Modality: Movement Analysis
• 6.3. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market Estimates & Forecasts, By Modality, 2021 - 2033
• 6.4. Small Molecules
  • 6.4.1. Small Molecules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Biologics
  • 6.5.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Cell and Gene Therapies
  • 6.6.1. Cell and Gene Therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market: Therapeutic Area Estimates & Trend Analysis

• 7.1. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market, By Therapeutic Area: Segment Dashboard
• 7.2. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market, By Therapeutic Area: Movement Analysis
• 7.3. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market Estimates & Forecasts, By Therapeutic Area, 2021 - 2033 (USD Million)
• 7.4. Oncology
  • 7.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Autoimmune & Inflammatory Diseases
  • 7.5.1. Autoimmune & Inflammatory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. CNS
  • 7.6.1. CNS Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Cardiovascular & Metabolic
  • 7.7.1. Cardiovascular & Metabolic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Infectious Diseases
  • 7.8.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.9. Rare Diseases
  • 7.9.1. Rare Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.10. Others
  • 7.10.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market: End Use Estimates & Trend Analysis

• 8.1. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market, By End Use: Segment Dashboard
• 8.2. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market, By End Use: Movement Analysis
• 8.3. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
• 8.4. Pharmaceutical and Biopharmaceutical Companies
  • 8.4.1. Pharmaceutical and Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Academic and Research Institutes
  • 8.5.1. Academic and Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Others
  • 8.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2025 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Global Regional Market Snapshot
• 9.4. North America
  • 9.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.2. U.S
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Competitive Scenario
    • 9.4.2.3. Regulatory Framework
    • 9.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.3. Canada
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Competitive Scenario
    • 9.4.3.3. Regulatory Framework
    • 9.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.4. Mexico
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Competitive Scenario
    • 9.4.4.3. Regulatory Framework
    • 9.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.5. Europe
  • 9.5.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.2. UK
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Competitive Scenario
    • 9.5.2.3. Regulatory Framework
    • 9.5.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.3. Germany
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Competitive Scenario
    • 9.5.3.3. Regulatory Framework
    • 9.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.4. France
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Competitive Scenario
    • 9.5.4.3. Regulatory Framework
    • 9.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.5. Italy
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Competitive Scenario
    • 9.5.5.3. Regulatory Framework
    • 9.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.6. Spain
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Competitive Scenario
    • 9.5.6.3. Regulatory Framework
    • 9.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.7. Denmark
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Competitive Scenario
    • 9.5.7.3. Regulatory Framework
    • 9.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.8. Sweden
    • 9.5.8.1. Key Country Dynamics
    • 9.5.8.2. Competitive Scenario
    • 9.5.8.3. Regulatory Framework
    • 9.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.9. Norway
    • 9.5.9.1. Key Country Dynamics
    • 9.5.9.2. Competitive Scenario
    • 9.5.9.3. Regulatory Framework
    • 9.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.6. Asia Pacific
  • 9.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.2. Japan
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Competitive Scenario
    • 9.6.2.3. Regulatory Framework
    • 9.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.3. China
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Competitive Scenario
    • 9.6.3.3. Regulatory Framework
    • 9.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.4. India
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Competitive Scenario
    • 9.6.4.3. Regulatory Framework
    • 9.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.5. Thailand
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Competitive Scenario
    • 9.6.5.3. Regulatory Framework
    • 9.6.5.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.6. South Korea
    • 9.6.6.1. Key Country Dynamics
    • 9.6.6.2. Competitive Scenario
    • 9.6.6.3. Regulatory Framework
    • 9.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.7. Australia
    • 9.6.7.1. Key Country Dynamics
    • 9.6.7.2. Competitive Scenario
    • 9.6.7.3. Regulatory Framework
    • 9.6.7.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.7. Latin America
  • 9.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.2. Brazil
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Competitive Scenario
    • 9.7.2.3. Regulatory Framework
    • 9.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.3. Argentina
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Competitive Scenario
    • 9.7.3.3. Regulatory Framework
    • 9.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.8. MEA
  • 9.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.2. South Africa
    • 9.8.2.1. Key Country Dynamics
    • 9.8.2.2. Competitive Scenario
    • 9.8.2.3. Regulatory Framework
    • 9.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.3. Saudi Arabia
    • 9.8.3.1. Key Country Dynamics
    • 9.8.3.2. Competitive Scenario
    • 9.8.3.3. Regulatory Framework
    • 9.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.4. UAE
    • 9.8.4.1. Key Country Dynamics
    • 9.8.4.2. Competitive Scenario
    • 9.8.4.3. Regulatory Framework
    • 9.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.5. Kuwait
    • 9.8.5.1. Key Country Dynamics
    • 9.8.5.2. Competitive Scenario
    • 9.8.5.3. Regulatory Framework
    • 9.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.6. Oman
    • 9.8.6.1. Key Country Dynamics
    • 9.8.6.2. Competitive Scenario
    • 9.8.6.3. Regulatory Framework
    • 9.8.6.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.7. Qatar
    • 9.8.7.1. Key Country Dynamics
    • 9.8.7.2. Competitive Scenario
    • 9.8.7.3. Regulatory Framework
    • 9.8.7.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Market Participant Categorization
• 10.2. Market Assessment Analysis, 2025 (Heat Map Analysis)
• 10.3. Company Profiles
  • 10.3.1. Parexel International (MA) Corporation
    • 10.3.1.1. Company Overview
    • 10.3.1.2. Financial Performance
    • 10.3.1.3. Service Benchmarking
    • 10.3.1.4. Strategic Initiatives
  • 10.3.2. ToxStrategies
    • 10.3.2.1. Company Overview
    • 10.3.2.2. Financial Performance
    • 10.3.2.3. Service Benchmarking
    • 10.3.2.4. Strategic Initiatives
  • 10.3.3. Certara
    • 10.3.3.1. Company Overview
    • 10.3.3.2. Financial Performance
    • 10.3.3.3. Service Benchmarking
    • 10.3.3.4. Strategic Initiatives
  • 10.3.4. Dark Horse Consulting Group
    • 10.3.4.1. Company Overview
    • 10.3.4.2. Financial Performance
    • 10.3.4.3. Service Benchmarking
    • 10.3.4.4. Strategic Initiatives
  • 10.3.5. ELIQUENT Life Sciences
    • 10.3.5.1. Company Overview
    • 10.3.5.2. Financial Performance
    • 10.3.5.3. Service Benchmarking
    • 10.3.5.4. Strategic Initiatives
  • 10.3.6. SciLucent
    • 10.3.6.1. Company Overview
    • 10.3.6.2. Financial Performance
    • 10.3.6.3. Service Benchmarking
    • 10.3.6.4. Strategic Initiatives
  • 10.3.7. Latham BioPharm Group (Sia Partners)
    • 10.3.7.1. Company Overview
    • 10.3.7.2. Financial Performance
    • 10.3.7.3. Service Benchmarking
    • 10.3.7.4. Strategic Initiatives
  • 10.3.8. Salamandra
    • 10.3.8.1. Company Overview
    • 10.3.8.2. Financial Performance
    • 10.3.8.3. Service Benchmarking
    • 10.3.8.4. Strategic Initiatives
  • 10.3.9. Akkeri Inc.
    • 10.3.9.1. Company Overview
    • 10.3.9.2. Financial Performance
    • 10.3.9.3. Service Benchmarking
    • 10.3.9.4. Strategic Initiatives
  • 10.3.10. Aclairo Pharmaceutical Development Group, Inc.
    • 10.3.10.1. Company Overview
    • 10.3.10.2. Financial Performance
    • 10.3.10.3. Service Benchmarking
    • 10.3.10.4. Strategic Initiatives
  • 10.3.11. Biologics Consulting Group, Inc.
    • 10.3.11.1. Company Overview
    • 10.3.11.2. Financial Performance
    • 10.3.11.3. Service Benchmarking
    • 10.3.11.4. Strategic Initiatives